News

Novo Nordisk's insulin aspart franchise is a DKK 10.6 billion ($1.5 billion) business worldwide, with NovoLog (known as NovoRapid outside ... Nordisk has developed a new version of the insulin ...
That suggests its top-selling insulin products like rapid-acting NovoRapid (insulin aspart), premix NovoMix (insulin aspart/insulin aspart protamine) and long-acting Tresiba (insulin degludec ...